Endothelins: A possible mechanism of cytostatics-induced cardiomyopathy

András Zsáry, Szófia Szûcs, Katalin Keltai, Tamás Schneider, András Rosta, Pál Sármán, Tamás Fenyvesi, I. Karádi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Endothelium responds to physical and chemical stimuli by synthesis and release of a variety of vasoactive and signal molecules. Cardiac performance is regulated by cardiac endothelial cells in a paracrine manner, analogous to vascular endothelial control of vascular tone. Endothelin-1 (ET-1), one of the most potent vasoconstrictor peptides, which is synthetized and released by endothelial cells. The role of ET-1 in some special pathological state is still unclear. Authors have investigated the effect of anthracyclines (maximal dose: 450 mg/bodysurface in m2) on left ventricular systolic and diastolic function and on the level of plasma ET-1, in 31 (13 male, aged 19-70 years, mean: 38.9) patients suffered from Hodgkin (24) and Non-Hodgkin (7) lymphomas. They have also studied the association between plasma ET-1 concentration and echocardiographic parameters. Serum ET-1 was measured by ELISA method. Left ventricular function analyzed by echocardiography: ejection fraction (EF), time velocity integral (VTI), E and A waves, E/A ratio, deceleration time (DT), Doppler index were assessed. Statistical analysis was made by the Wilcoxon rank test. ET-1 plasma level decreased significantly after therapy (5.6 ± 3.5 vs. 3.1 ± 0.9 pg/ml, P <0.0006). EF (56.4 ± 5.0% vs. 48.7 ± 5.1%, P <0.0001) decreased, and DT (168.1 ± 36.8 ms vs. 206.5 ± 58.8 ms, P <0.0073 increased significantly after administration of anthracycline, showing that both systolic and diastolic left ventricular performance was deteriorated. There was no difference in other echocardiographic parameters before and after therapy. In conclusion, decrease of serum ET-1 concentration might be a result of anthracyclin's direct cytotoxic effect and the decreasing level of ET-1 may play a role in the reduction of the EF. More studies are needed to evaluate the presence and severity of endothelial damage, and long-term follow-up may reveal the importance of low ET-1 level and may show the time is needed for the restoration of the ET-1 concentration to the basic level after cessation of cytostatic therapy.

Original languageEnglish
Pages (from-to)351-355
Number of pages5
JournalLeukemia and Lymphoma
Volume45
Issue number2
DOIs
Publication statusPublished - Feb 2004

Fingerprint

Endothelins
Cytostatic Agents
Endothelin-1
Cardiomyopathies
Deceleration
Anthracyclines
Blood Vessels
Endothelial Cells
Vasoconstrictor Agents
Nonparametric Statistics
Serum
Hodgkin Disease
Left Ventricular Function
Non-Hodgkin's Lymphoma
Endothelium
Echocardiography
Therapeutics
Enzyme-Linked Immunosorbent Assay
Peptides

Keywords

  • Anthracyclines
  • Cardiomyopathy
  • Echocardiography
  • Endothelin-1
  • Ventricular function

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Zsáry, A., Szûcs, S., Keltai, K., Schneider, T., Rosta, A., Sármán, P., ... Karádi, I. (2004). Endothelins: A possible mechanism of cytostatics-induced cardiomyopathy. Leukemia and Lymphoma, 45(2), 351-355. https://doi.org/10.1080/10428190310001593607

Endothelins : A possible mechanism of cytostatics-induced cardiomyopathy. / Zsáry, András; Szûcs, Szófia; Keltai, Katalin; Schneider, Tamás; Rosta, András; Sármán, Pál; Fenyvesi, Tamás; Karádi, I.

In: Leukemia and Lymphoma, Vol. 45, No. 2, 02.2004, p. 351-355.

Research output: Contribution to journalArticle

Zsáry, A, Szûcs, S, Keltai, K, Schneider, T, Rosta, A, Sármán, P, Fenyvesi, T & Karádi, I 2004, 'Endothelins: A possible mechanism of cytostatics-induced cardiomyopathy', Leukemia and Lymphoma, vol. 45, no. 2, pp. 351-355. https://doi.org/10.1080/10428190310001593607
Zsáry A, Szûcs S, Keltai K, Schneider T, Rosta A, Sármán P et al. Endothelins: A possible mechanism of cytostatics-induced cardiomyopathy. Leukemia and Lymphoma. 2004 Feb;45(2):351-355. https://doi.org/10.1080/10428190310001593607
Zsáry, András ; Szûcs, Szófia ; Keltai, Katalin ; Schneider, Tamás ; Rosta, András ; Sármán, Pál ; Fenyvesi, Tamás ; Karádi, I. / Endothelins : A possible mechanism of cytostatics-induced cardiomyopathy. In: Leukemia and Lymphoma. 2004 ; Vol. 45, No. 2. pp. 351-355.
@article{9c7ddce58f2141728047a46d609efd2f,
title = "Endothelins: A possible mechanism of cytostatics-induced cardiomyopathy",
abstract = "Endothelium responds to physical and chemical stimuli by synthesis and release of a variety of vasoactive and signal molecules. Cardiac performance is regulated by cardiac endothelial cells in a paracrine manner, analogous to vascular endothelial control of vascular tone. Endothelin-1 (ET-1), one of the most potent vasoconstrictor peptides, which is synthetized and released by endothelial cells. The role of ET-1 in some special pathological state is still unclear. Authors have investigated the effect of anthracyclines (maximal dose: 450 mg/bodysurface in m2) on left ventricular systolic and diastolic function and on the level of plasma ET-1, in 31 (13 male, aged 19-70 years, mean: 38.9) patients suffered from Hodgkin (24) and Non-Hodgkin (7) lymphomas. They have also studied the association between plasma ET-1 concentration and echocardiographic parameters. Serum ET-1 was measured by ELISA method. Left ventricular function analyzed by echocardiography: ejection fraction (EF), time velocity integral (VTI), E and A waves, E/A ratio, deceleration time (DT), Doppler index were assessed. Statistical analysis was made by the Wilcoxon rank test. ET-1 plasma level decreased significantly after therapy (5.6 ± 3.5 vs. 3.1 ± 0.9 pg/ml, P <0.0006). EF (56.4 ± 5.0{\%} vs. 48.7 ± 5.1{\%}, P <0.0001) decreased, and DT (168.1 ± 36.8 ms vs. 206.5 ± 58.8 ms, P <0.0073 increased significantly after administration of anthracycline, showing that both systolic and diastolic left ventricular performance was deteriorated. There was no difference in other echocardiographic parameters before and after therapy. In conclusion, decrease of serum ET-1 concentration might be a result of anthracyclin's direct cytotoxic effect and the decreasing level of ET-1 may play a role in the reduction of the EF. More studies are needed to evaluate the presence and severity of endothelial damage, and long-term follow-up may reveal the importance of low ET-1 level and may show the time is needed for the restoration of the ET-1 concentration to the basic level after cessation of cytostatic therapy.",
keywords = "Anthracyclines, Cardiomyopathy, Echocardiography, Endothelin-1, Ventricular function",
author = "Andr{\'a}s Zs{\'a}ry and Sz{\'o}fia Sz{\^u}cs and Katalin Keltai and Tam{\'a}s Schneider and Andr{\'a}s Rosta and P{\'a}l S{\'a}rm{\'a}n and Tam{\'a}s Fenyvesi and I. Kar{\'a}di",
year = "2004",
month = "2",
doi = "10.1080/10428190310001593607",
language = "English",
volume = "45",
pages = "351--355",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Endothelins

T2 - A possible mechanism of cytostatics-induced cardiomyopathy

AU - Zsáry, András

AU - Szûcs, Szófia

AU - Keltai, Katalin

AU - Schneider, Tamás

AU - Rosta, András

AU - Sármán, Pál

AU - Fenyvesi, Tamás

AU - Karádi, I.

PY - 2004/2

Y1 - 2004/2

N2 - Endothelium responds to physical and chemical stimuli by synthesis and release of a variety of vasoactive and signal molecules. Cardiac performance is regulated by cardiac endothelial cells in a paracrine manner, analogous to vascular endothelial control of vascular tone. Endothelin-1 (ET-1), one of the most potent vasoconstrictor peptides, which is synthetized and released by endothelial cells. The role of ET-1 in some special pathological state is still unclear. Authors have investigated the effect of anthracyclines (maximal dose: 450 mg/bodysurface in m2) on left ventricular systolic and diastolic function and on the level of plasma ET-1, in 31 (13 male, aged 19-70 years, mean: 38.9) patients suffered from Hodgkin (24) and Non-Hodgkin (7) lymphomas. They have also studied the association between plasma ET-1 concentration and echocardiographic parameters. Serum ET-1 was measured by ELISA method. Left ventricular function analyzed by echocardiography: ejection fraction (EF), time velocity integral (VTI), E and A waves, E/A ratio, deceleration time (DT), Doppler index were assessed. Statistical analysis was made by the Wilcoxon rank test. ET-1 plasma level decreased significantly after therapy (5.6 ± 3.5 vs. 3.1 ± 0.9 pg/ml, P <0.0006). EF (56.4 ± 5.0% vs. 48.7 ± 5.1%, P <0.0001) decreased, and DT (168.1 ± 36.8 ms vs. 206.5 ± 58.8 ms, P <0.0073 increased significantly after administration of anthracycline, showing that both systolic and diastolic left ventricular performance was deteriorated. There was no difference in other echocardiographic parameters before and after therapy. In conclusion, decrease of serum ET-1 concentration might be a result of anthracyclin's direct cytotoxic effect and the decreasing level of ET-1 may play a role in the reduction of the EF. More studies are needed to evaluate the presence and severity of endothelial damage, and long-term follow-up may reveal the importance of low ET-1 level and may show the time is needed for the restoration of the ET-1 concentration to the basic level after cessation of cytostatic therapy.

AB - Endothelium responds to physical and chemical stimuli by synthesis and release of a variety of vasoactive and signal molecules. Cardiac performance is regulated by cardiac endothelial cells in a paracrine manner, analogous to vascular endothelial control of vascular tone. Endothelin-1 (ET-1), one of the most potent vasoconstrictor peptides, which is synthetized and released by endothelial cells. The role of ET-1 in some special pathological state is still unclear. Authors have investigated the effect of anthracyclines (maximal dose: 450 mg/bodysurface in m2) on left ventricular systolic and diastolic function and on the level of plasma ET-1, in 31 (13 male, aged 19-70 years, mean: 38.9) patients suffered from Hodgkin (24) and Non-Hodgkin (7) lymphomas. They have also studied the association between plasma ET-1 concentration and echocardiographic parameters. Serum ET-1 was measured by ELISA method. Left ventricular function analyzed by echocardiography: ejection fraction (EF), time velocity integral (VTI), E and A waves, E/A ratio, deceleration time (DT), Doppler index were assessed. Statistical analysis was made by the Wilcoxon rank test. ET-1 plasma level decreased significantly after therapy (5.6 ± 3.5 vs. 3.1 ± 0.9 pg/ml, P <0.0006). EF (56.4 ± 5.0% vs. 48.7 ± 5.1%, P <0.0001) decreased, and DT (168.1 ± 36.8 ms vs. 206.5 ± 58.8 ms, P <0.0073 increased significantly after administration of anthracycline, showing that both systolic and diastolic left ventricular performance was deteriorated. There was no difference in other echocardiographic parameters before and after therapy. In conclusion, decrease of serum ET-1 concentration might be a result of anthracyclin's direct cytotoxic effect and the decreasing level of ET-1 may play a role in the reduction of the EF. More studies are needed to evaluate the presence and severity of endothelial damage, and long-term follow-up may reveal the importance of low ET-1 level and may show the time is needed for the restoration of the ET-1 concentration to the basic level after cessation of cytostatic therapy.

KW - Anthracyclines

KW - Cardiomyopathy

KW - Echocardiography

KW - Endothelin-1

KW - Ventricular function

UR - http://www.scopus.com/inward/record.url?scp=0842322862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842322862&partnerID=8YFLogxK

U2 - 10.1080/10428190310001593607

DO - 10.1080/10428190310001593607

M3 - Article

C2 - 15101723

AN - SCOPUS:0842322862

VL - 45

SP - 351

EP - 355

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -